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Endocannabinoid antagonism as a treatment for obesity and the metabolic syndrome became a hugely anticipated area of
pharmacology at the start of the century. The CB1 receptor antagonist Rimonabant entered the European mass market on the back
of several trials showing weight loss beneﬁts alongside improvements in numerous other elements of the metabolic syndrome.
However, the drug was quickly withdrawn due to the emergence of signiﬁcant side eﬀects—notably severe mood disorders. This
paper provides a brief overview of the Rimonabant story and places the recent spate of FDA rejections of other centrally acting
weight loss drugs entering Phase 3 trials in this context.
1.Introduction
The appetite regulating eﬀects of plant-derived cannabinoids
have been known for centuries. In the late 1980s and early
1990s, the discovery of speciﬁc cannabinoid G-protein-
coupled receptors, CB1 and CB2, and their endogenous
ligands, the endocannabinoids, opened up a major area
of research into the pharmacological manipulation of this
system. It culminated with the extensive clinical trialling
and European marketing of Rimonabant, Sanoﬁ-Aventis’
speciﬁc CB1 receptor inverse agonist (functional antagonist)
as an antiobesity agent, and ultimately its suspension due
to postmarketing safety concerns. This paper provides a
synopsis of this story and the lessons to be learned from it
with the current generation of centrally acting weight loss
drugs in late-stage clinical trials.
2. CannabinoidReceptor Antagonism for
the Treatment of Obesity and the Metabolic
Syndrome
The endogenous cannabinoid system is widely distributed,
and its physiology is not yet fully elucidated. The endo-
cannabinoids themselves, anandamide and 2-arachidonoyl
glycerol, are not stored as secretory neurotransmitters but
are neuromodulators produced at the required site of action
and rapidly metabolised [1]. CB2 receptors are found largely
on immune cells where they modulate proinﬂammatory
cytokine suppression [2]. More interest and development
has occurred around the CB1 receptor, which is distributed
abundantly in the central nervous system (particularly the
hippocampus, basal ganglia, and hypothalamus) but has also
beenidentiﬁedthroughouttheGItract,inadiposetissueand
the cardiovascular system.
The inhibition of drug-seeking behaviour by CB1
receptor antagonism [3] and observed attenuated reward
behavioursintheCB1receptorKOmouse[4] provide strong
evidence for the involvement of the endocannabinoid system
in motivated behaviour and hedonic responses. The induc-
tion of anxiety by cannabinoid receptor antagonism was
reported a decade prior to the removal of Rimonabant from
market due to adverse psychiatric eﬀects [5]. Nevertheless,
cannabinoid receptor antagonists retain an important place
in the testing of animal models of addiction and conditioned
behaviour and may in the future have a role in the treatment
of drug dependency.
Cannabinoid modulation of hedonic responses also
extends to the rewarding aspects of food consumption,
which explains some of the appetite-reducing eﬀects of
Rimonabant. However, the eﬀects of cannabinoid antago-
nism on appetite regulation and metabolism are far more
intricate. In addition to the hedonic modulation of food2 Journal of Obesity
intake in higher reward centres, the endocannabinoid system
also strongly interacts with the peptidergic hypothalamic
circuitry governing the homeostatic regulation of appetite
and food intake [6]. Furthermore, pair-feeding studies reveal
that the leaner phenotype of the CB1 receptor KO mouse is
in part due to food-intake-independent mechanisms, such
as elevated energy expenditure [7]. Many of these metabolic
eﬀects may be explained by actions on brain CB1 receptors
inﬂuencing autonomic output to the gastrointestinal tract,
adipose tissue, and liver. Experimentally distinguishing these
centrally mediated peripheral eﬀects from direct eﬀects on
peripherally located CB1 receptors (e.g., in adipose tissue
or pancreatic islet cells) is diﬃcult and not yet conclusive.
However, there remains considerable interest in the role
of peripheral CB1 receptors in the regulation of metabolic
processes and, as a result, the potential of developing
cannabinoid receptor antagonists that do not cross the blood
brain barrier as a treatment for the metabolic syndrome [8].
This is due to the wider beneﬁcial eﬀects on glucose and lipid
parameters observed in the human trials described below,
apparently above and beyond those expected as a result of
appetite-inhibition-driven weight loss alone.
3.ClinicalTrialsAssessing SafetyandEfﬁcacy
of Rimonabant
The blockade of the CB1 receptor as a treatment for
obesity has been explored in several clinical trials. In one
study, obese or overweight patients (BMI > 27kg/m2)w i t h
dyslipidaemia, and/or hypertension, were randomised to
double-blind treatment with placebo or Rimonabant (5mg
or 20mg once daily). All groups were also encouraged to
follow a mild hypocaloric diet [9]. Rimonabant at a dose
of 20mg/day, combined with a hypocaloric diet over 1
year, promoted a signiﬁcant decrease in bodyweight and
waist circumference and improvement in cardiovascular
risk factors. After one year, patients treated with higher-
dose Rimonabant had reduced glucose and insulin levels
2 hours after oral glucose tolerance testing compared with
placebo. Interestingly, this beneﬁt continued to be seen at 2
years, when weight stabilisation had occurred. In this study
Rimonabant was reported as generally well tolerated with
mild and transient side eﬀects.
The Rimonabant in Obesity-Lipids (RIO-Lipids) trial
also studied the eﬀects of Rimonabant on metabolic risk fac-
tors in high-risk patients who were overweight or obese and
had dyslipidaemia [10]. The investigators randomly assigned
over 1000 overweight or obese patients with untreated
dyslipidaemia to double-blinded treatment with placebo or
Rimonabant for 12 months in addition to a hypocaloric diet.
Rimonabant at a dose of 20mg was associated with a sig-
niﬁcant mean weight loss, reduction in waist circumference,
increase in HDL cholesterol, and reduction in triglycerides,
compared with placebo. Rimonabant at a dose of 20mg also
resulted in an increase in plasma adiponectin levels, a change
that was partly independent of weight loss alone. The most
frequent adverse events resulting in discontinuation of the
drug were depression, anxiety, and nausea.
The RIO-North America Study Group also assessed the
eﬃcacy and safety of Rimonabant alongside lifestyle modiﬁ-
cation for sustained changes in weight and cardiometabolic
risk factors over 2 years [11]. Rimonabant treatment in
addition to diet promoted modest but sustained reductions
in weight and waist circumference and favourable changes in
cardiometabolic risk factors. This trial was limited by a high
drop-out rate. The most common drug-related adverse event
in this study was nausea.
The RIO-Diabetes trial assessed the eﬃcacy and safety
of Rimonabant in overweight or obese patients with type 2
diabetes inadequately controlled by metformin or sulpho-
nylureas. Over 1000 overweight or obese type 2 diabetes
patients with a haemoglobin A1c of 6.5–10.0% already
on metformin or sulphonylurea were randomly assigned
to received placebo, 5mg/day Rimonabant, or 20mg/day
Rimonabant for 1 year in addition to a hypocaloric diet and
advice for increased physical activity [12]. Rimonabant, at a
dose of 20mg/day, in combination with diet and exercise,
produced a clinically meaningful reduction in bodyweight
and improved HbA1c and a number of cardiovascular and
metabolic risk factors. The incidence of adverse events that
led to discontinuation was slightly greater in the 20mg/day
Rimonabant group, mainly due to depressed mood disor-
ders, nausea, and dizziness [12].
The SERENADE trial (The Study Evaluating Rimona-
bant Eﬃcacy in Drug-Naive Diabetic Patients) assessed the
glucose-lowering eﬃcacy and safety of Rimonabant in drug-
naive type 2 diabetic patients. In this 6-month, randomized
double-blind placebo-controlled trial, Rimonabant resulted
in improvements in glycaemic control, body weight, and
lipid proﬁle in drug-naive type 2 diabetic patients [13].
Two meta-analyses [14, 15] conﬁrmed that Rimona-
bant treatment led to clinically meaningful weight loss,
reduction in waist circumference, and improvements in
several metabolic risk factors. However, ﬁndings from a
meta-analysis of all published randomised controlled trials
suggested that 20mg per day Rimonabant increases the risk
of psychiatric adverse events (depressed mood disorders and
anxiety)despitedepressedmoodbeinganexclusioncriterion
inthesetrials.Rimonabantcausedsigniﬁcantlymoreadverse
events than did placebo and 1.4 times more serious adverse
events [15]. Patients given Rimonabant were 2.5 times more
likely to discontinue the treatment because of depressive
mooddisordersthanwerethosegivenplacebo.Furthermore,
anxiety caused more patients to discontinue treatment in
Rimonabant groups than in placebo groups.
In The US Food and Drug Administration analysis of the
four major trials as well as unpublished trials, psychiatric
adverse events were found to be more common with
Rimonabant (20mg/day) than placebo [16]. Furthermore,
two deaths from suicide were reported in patients taking
Rimonabant. The drug was never approved in the United
States for the treatment of obesity. The marketing approval
for Rimonabant has since been removed by the European
Regulatory Authorities.
4.Lessons Learned
Obesity-related diseases account for almost 10% of medical
expenditure in the USA, or an estimated $92 billion a yearJournal of Obesity 3
[17]. By 2030, the prevalence of overweight and obesity in
the USA is projected to rise to 86.3% [18], forecast alongside
a reversal of the 20th century gains in life expectancy due to
the adverse health consequences of obesity [19]. The need
and market for eﬃc a c i o u sw e i g h tl o s sa g e n t si st h e r e f o r e
enormous. However, the history of antiobesity agents is
littered with examples of drugs whose risks outweighed any
potential weight loss beneﬁts. Centrally mediated increased
autonomicoutputhasaccountedforexcesscardiacmortality,
from the prescription of amphetamine-like drugs in the
middle part of the 20th century, all the way up until the
ﬁndings of the SCOUT trial which prompted the removal
of Sibutramine from worldwide markets in late 2010 [20].
This followed in the wake of the refusal of the US FDA to
approve the use of Rimonabant and the European Medicines
Agency withdrawal of the drug, following postmarketing
surveillance studies which conﬁrmed a greater risk of
depressive disorders amongst users. Both of these examples
highlight the risks associated with the use of centrally
acting weight loss agents, whose eﬀects on appetite are
counterbalanced by numerous other potentially hazardous
eﬀects on mood, reward, dependence, and autonomic tone.
With our current incomplete understanding of the physi-
ology governing food intake, many of these eﬀects may be
subtle or unpredictable and may only become apparent in
postmarketing surveillance stage, when many more subjects
are exposed to the drug. In the light of this, the FDA failed
to endorse three new anti-obesity agents in 2010 because
of safety concerns: Phentermine/Topiramate (Qnexa-Vivus,
Inc.), Bupropion/Naltrexone (Contrave-Orexigen Therapeu-
tics), and Lorcaserin Hydrochloride (Lorqess-Arena Pharma-
ceuticals). In the case of Qnexa, despite very promising late
stage clinical trials demonstrating over 9% body weight loss
in the treatment group [21], the FDA expressed concerns
about serious potential adverse eﬀects including suicidal
ideation, cognitive issues, and tachycardia. There was also
major concern over the drug’s teratogenic potential, but
at present Vivus are planning to resubmit application for
approval to the FDA to limit its use in patients past child-
bearing age. In the case of Contrave, the advisory panel
endorsed the drug, but the FDA decided it needed to see
more cardiovascular data before it could be approved. Thus,
against a background of growing suspicion and wariness,
the search for eﬃcacious, safe, and well-tolerated weight loss
pharmacotherapies remains as pressing and elusive as ever.
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